IL146701A0 - Therapy for andropause using estrogen agonists/antagonists and testosterone - Google Patents

Therapy for andropause using estrogen agonists/antagonists and testosterone

Info

Publication number
IL146701A0
IL146701A0 IL14670101A IL14670101A IL146701A0 IL 146701 A0 IL146701 A0 IL 146701A0 IL 14670101 A IL14670101 A IL 14670101A IL 14670101 A IL14670101 A IL 14670101A IL 146701 A0 IL146701 A0 IL 146701A0
Authority
IL
Israel
Prior art keywords
andropause
testosterone
antagonists
therapy
estrogen agonists
Prior art date
Application number
IL14670101A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL146701A0 publication Critical patent/IL146701A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14670101A 2000-11-30 2001-11-22 Therapy for andropause using estrogen agonists/antagonists and testosterone IL146701A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25007100P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
IL146701A0 true IL146701A0 (en) 2002-07-25

Family

ID=22946195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14670101A IL146701A0 (en) 2000-11-30 2001-11-22 Therapy for andropause using estrogen agonists/antagonists and testosterone

Country Status (15)

Country Link
US (2) US20020115676A1 (de)
EP (1) EP1210951B1 (de)
JP (1) JP2002193809A (de)
KR (1) KR20020042505A (de)
AT (1) ATE288303T1 (de)
AU (1) AU779964B2 (de)
CA (1) CA2363935A1 (de)
DE (1) DE60108710T2 (de)
DK (1) DK1210951T3 (de)
ES (1) ES2233570T3 (de)
HU (1) HUP0105201A3 (de)
IL (1) IL146701A0 (de)
NZ (1) NZ515822A (de)
PT (1) PT1210951E (de)
ZA (1) ZA200109836B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
KR101180896B1 (ko) * 2003-05-05 2012-09-07 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 주사용 가교결합된 폴리머 제제 및 그의 용도
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii
EP1550440A1 (de) * 2003-12-15 2005-07-06 Laboratoires Besins International Verwendung von 4-hydroxytamoxifen zur Herstellung eines Arzneimittels zur Behandlung von Gynäkomastie
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005066337A2 (en) * 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
EP2307026B1 (de) 2008-07-04 2016-04-13 The Heart Research Institute Limited Verwendung von androgenen zur gefässregeneration und endothelreparatur
KR102335267B1 (ko) * 2017-03-16 2021-12-06 주식회사 자연과학기술 무지개송어 정소로부터 테스토스테론의 추출방법
US20240000799A1 (en) * 2020-12-04 2024-01-04 Lennham Pharmaceuticals, Inc. Deuterated forms of testosterone and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585905A (en) * 1897-07-06 Frank bonileor
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata

Also Published As

Publication number Publication date
ATE288303T1 (de) 2005-02-15
ZA200109836B (en) 2003-05-29
US20020115676A1 (en) 2002-08-22
HUP0105201A2 (hu) 2002-12-28
HU0105201D0 (en) 2002-01-28
CA2363935A1 (en) 2002-05-30
EP1210951A3 (de) 2003-09-24
EP1210951A2 (de) 2002-06-05
DE60108710T2 (de) 2006-05-04
AU9516501A (en) 2002-06-06
AU779964B2 (en) 2005-02-24
ES2233570T3 (es) 2005-06-16
EP1210951B1 (de) 2005-02-02
KR20020042505A (ko) 2002-06-05
NZ515822A (en) 2003-05-30
HUP0105201A3 (en) 2004-04-28
US20050288325A1 (en) 2005-12-29
PT1210951E (pt) 2005-04-29
DE60108710D1 (de) 2005-03-10
DK1210951T3 (da) 2005-03-29
JP2002193809A (ja) 2002-07-10

Similar Documents

Publication Publication Date Title
ZA200109836B (en) Therapy for andropause using estrogen agonists/antagonists and testosterone.
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
EP1177787A3 (de) Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt
ZA200200596B (en) Method of treating certain cancers using an estrogen agonist/antagonist.
AU9393601A (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
UA83620C2 (ru) Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
AU2001264713A1 (en) Methods and apparatus for preventing software modifications from invalidating previously passed integration tests
AU2002354079A1 (en) An apparatus for fitting the protecting femoral neck device
SI1373256T1 (sl) Antagonisti CCR5, uporabni pri zdravljenju AIDS-a
GB0011358D0 (en) Novel use
GB9804886D0 (en) Therapeutic combination
SG153647A1 (en) Antineoplastic combinations
PL356658A1 (en) Drug delivery device, especially for the delivery of androgens
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
HU9702039D0 (en) Estrogen agonist/antagonists treatment of atheroscerosis
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
AU6909400A (en) Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction
TW525623U (en) Improvement for irregular yarn feeding device
HU9902674D0 (en) Estrogen agonists/antagonists
MXPA04001878A (es) Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
AU2002366272A8 (en) Edg-receptor agonist for the treatment of hypertension
TW483307U (en) Device for attracting carambola bugs
AU7986000A (en) Colorimetric test for agents that induce mitrochondrial dysfunction
AU2002354536A1 (en) Device for stocking and supplying parts